Premium
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced‐intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia
Author(s) -
Tholouli Eleni,
Liakopoulou Effie,
Greenfield Hayley M.,
Shaw Bronwen E.,
Tauro Sudhir,
Byrne Jennifer L.,
Dennis Mike,
Burthem John,
Lucas Guy S.,
Craddock Charles,
Russell Nigel H.,
Liu Yin John A.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07184.x
Subject(s) - alemtuzumab , myeloid leukaemia , medicine , conditioning , oncology , stem cell , myeloid , immunology , transplantation , biology , genetics , statistics , mathematics